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Reply to Townes-Anderson: RPE65 Gene Therapy Does Not Alter the Natural
History of Retinal Degeneration
Abstract
We appreciate the interest shown by TownesAnderson in our article examining the natural history of
retinal degeneration in Leber congenital amaurosis caused by retinal pigment epithelium-specific protein
65kDa (RPE65) mutations and evaluating the consequences of gene augmentation therapy. TownesAnderson’s remarks focused on the final phrase of the last sentence of the Discussion of our article. In
the full sentence, we suggested that in the future, agents to reduce cell death could be delivered in
combination with a more advanced version of the gene augmentation therapy that reaches not only
remaining rods and extrafoveal cones but also foveal cone photoreceptors.
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LETTER

Reply to Townes-Anderson: RPE65 gene
therapy does not alter the natural history
of retinal degeneration
We appreciate the interest shown by TownesAnderson (1) in our article examining the
natural history of retinal degeneration in
Leber congenital amaurosis caused by retinal
pigment epithelium-speciﬁc protein 65kDa
(RPE65) mutations and evaluating the consequences of gene augmentation therapy (2).
Townes-Anderson’s remarks focused on the
ﬁnal phrase of the last sentence of the Discussion of our article. In the full sentence,
we suggested that in the future, agents to
reduce cell death could be delivered in combination with a more advanced version of
the gene augmentation therapy that reaches
not only remaining rods and extrafoveal
cones but also foveal cone photoreceptors.
Towne-Anderson made the constructive
point that consideration should be given in
future versions of human RPE65 gene therapy to a speciﬁc rod photoreceptor celldeath pathway (3). We are familiar with
the Townes-Anderson hypothesis involving
G-protein activation by mislocalized opsin,
and we have recently cited this hypothesis
as potentially relevant for our work demonstrating successful arrest of retinal degeneration by gene augmentation therapy
in the RPGR form of X-linked retinitis pigmentosa (4). However, disease mechanisms
in the retinoid deﬁciency caused by RPE65
mutations and in the ciliopathy caused by
RPGR mutations are likely to be different.
It is important to note that chromophore in
RPE65-mutant retinas is nearly undetectable and thus the majority of mislocalized
opsin molecules are not likely to be bound
to chromophore. The protection from bright
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light in Rpe65-deﬁcient mice—as opposed to
exacerbation of degeneration—argues against
a primary signaling pathway involving photoactivation of mislocalized isorhodopsin or
rhodopsin. Alternatively, it could be argued
that mislocalized free opsin is involved. Indeed, there is evidence that constitutive activation of G protein by free opsin contributes to cell death in Rpe65-deﬁciency, but
whether signaling originates from free opsin
correctly localized to rod outer segments or
mislocalized to the inner segments remains
unknown.
In patients who received gene augmentation therapy, there is a likely increase in 11cis-retinal chromophore availability to rods
and extrafoveal cones (5). According to the
Townes-Anderson hypothesis, the increase
in chromophore produced by gene therapy
together with ambient light should have
resulted in activation of mislocalized rhodopsin (1). Such signaling would be predicted
to accelerate the rate of cell loss beyond that
measured in the natural history of disease.
However, the rate of degeneration within
the retinal regions that received gene therapy was not faster than the natural history
(2), and thus did not support the TownesAnderson hypothesis.
In summary, we ﬁnd no speciﬁc support in our data for the hypothesis advanced by Townes-Anderson; however,
we wholeheartedly agree with the sentiment that we should proceed cautiously
to improve the outcomes of retinal gene
augmentation therapy including RPE65
gene therapy.
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